PURPOSE: Ovarian cancer is the fifth leading cause of cancer-related deaths among American women. Platinum-based chemotherapy, such as cisplatin, represents the standard-of-care for ovarian cancer. However, toxicity and acquired resistance to cisplatin have proven challenging in the treatment of patients with ovarian cancer. EXPERIMENTAL DESIGN: Using a genetically engineered mouse model of ovarian endometrioid adenocarcinoma (OEA) in combination with molecular-imaging technologies, we studied the activation of the AKT serine/threonine kinase in response to long-term cisplatin therapy. RESULTS: Treatment of cells in culture and tumor-bearing animals with cisplatin resulted in activation of AKT, a key mediator of cell survival. On the basis of these results, we investigated the therapeutic use of AKT inhibition in combination with cisplatin, which resulted in enhanced and prolonged induction of apoptosis and in significantly improved tumor control as compared with either agent alone. CONCLUSION: These results provide an impetus for clinical trials using combination therapy. To facilitate these trials, we also show the use of diffusion-weighted MRI as an imaging biomarker for evaluation of therapeutic efficacy in OEA.
PURPOSE:Ovarian cancer is the fifth leading cause of cancer-related deaths among American women. Platinum-based chemotherapy, such as cisplatin, represents the standard-of-care for ovarian cancer. However, toxicity and acquired resistance to cisplatin have proven challenging in the treatment of patients with ovarian cancer. EXPERIMENTAL DESIGN: Using a genetically engineered mouse model of ovarian endometrioid adenocarcinoma (OEA) in combination with molecular-imaging technologies, we studied the activation of the AKTserine/threonine kinase in response to long-term cisplatin therapy. RESULTS: Treatment of cells in culture and tumor-bearing animals with cisplatin resulted in activation of AKT, a key mediator of cell survival. On the basis of these results, we investigated the therapeutic use of AKT inhibition in combination with cisplatin, which resulted in enhanced and prolonged induction of apoptosis and in significantly improved tumor control as compared with either agent alone. CONCLUSION: These results provide an impetus for clinical trials using combination therapy. To facilitate these trials, we also show the use of diffusion-weighted MRI as an imaging biomarker for evaluation of therapeutic efficacy in OEA.
Authors: Daniela M Dinulescu; Tan A Ince; Bradley J Quade; Sarah A Shafer; Denise Crowley; Tyler Jacks Journal: Nat Med Date: 2004-12-26 Impact factor: 53.440
Authors: H Shibata; K Toyama; H Shioya; M Ito; M Hirota; S Hasegawa; H Matsumoto; H Takano; T Akiyama; K Toyoshima; R Kanamaru; Y Kanegae; I Saito; Y Nakamura; K Shiba; T Noda Journal: Science Date: 1997-10-03 Impact factor: 47.728
Authors: Siqing Fu; Bryan T Hennessy; Chaan S Ng; Zhenlin Ju; Kevin R Coombes; Judith K Wolf; Anil K Sood; Charles F Levenback; Robert L Coleman; John J Kavanagh; David M Gershenson; Maurie Markman; Kristine Dice; Adrienne Howard; Jane Li; Yang Li; Katherine Stemke-Hale; Mary Dyer; Edward Atkinson; Ed Jackson; Vikas Kundra; Razelle Kurzrock; Robert C Bast; Gordon B Mills Journal: Gynecol Oncol Date: 2012-04-06 Impact factor: 5.482
Authors: Andrea Flesken-Nikitin; Kyung-Chul Choi; Jessica P Eng; Elena N Shmidt; Alexander Yu Nikitin Journal: Cancer Res Date: 2003-07-01 Impact factor: 12.701
Authors: Jeffrey D Seidman; Iren Horkayne-Szakaly; Moutaz Haiba; Charles R Boice; Robert J Kurman; Brigitte M Ronnett Journal: Int J Gynecol Pathol Date: 2004-01 Impact factor: 2.762
Authors: Michael Fraser; Brendan M Leung; Xiaojuan Yan; Han C Dan; Jin Q Cheng; Benjamin K Tsang Journal: Cancer Res Date: 2003-11-01 Impact factor: 12.701
Authors: Sudhir B Kondapaka; Sheo S Singh; Girija P Dasmahapatra; Edward A Sausville; Krishnendu K Roy Journal: Mol Cancer Ther Date: 2003-11 Impact factor: 6.261